Prescript-assist
probiotic-prebiotic treatment for irritable bowel
syndrome:
an
open-label, partially controlled, 1-year extension of a
previously published controlled clinical trial.
"...the
rate of remissions was 81.5% to 100% (P < 0.003)."
OBJECTIVE: The aim of this study was to extend a
previous 2-week assessment of a probiotic-prebiotic
complex in patients with irritable bowel syndrome (IBS).
METHODS: In this open-label, partially controlled,
1-year (14 [2] months) extension study, data were
collected from patients with IBS who continued treatment
following a 2-week study of the efficacy of the
probiotic-prebiotic complex. Data were collected at 2
and approximately 60 weeks after the end of the original
study.
RESULTS: A total of 25 patients entered the 2-week
extension and 22 completed the approximately 60-week
follow-up study (20 women, 2 men; age range, 20-70
years; all white). Results in the control group 2 weeks
after crossover to treatment were similar to those from
the original study, with reductions in IBS subsyndromes,
as follows: general ill feelings/nausea (P < 0.001),
indigestion/flatulence (P < 0.001), and marginally
colitis (P < 0.03 [1-tailed]). Treatment was associated
with a continued reduction in general ill
feelings/nausea at 4 weeks (P < 0.007). At >or=52-week
follow-up, the rate of remissions was 81.5% to 100%
(P < 0.003).
CONCLUSION: Based on the results from the present
1-year extension study, treatment with this
probiotic-prebiotic complex may be an option for
short-term (2-4 weeks) and long-term ( approximately
60-week) reductions in IBS symptoms.
PMID:
17692729 [PubMed - indexed for MEDLINE]
Reference
page:
http://www.ncbi.nlm.nih.gov/pubmed/17692729?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA